In vitro evaluation of photodynamic therapy using redox-responsive nanoparticles carrying PpIX

Author(s)

Leite, Ilaiali Souza ; Vivero-Escoto, Juan Luis ; Lyles, Zachary ; Bagnato, Vanderlei Salvador ; Inada, Natalia Mayumi ; Kessel, DH ; Hasan, T

• Document type: Journal article
• Source: OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XXVII; v. 10476, p. 8-pg., 2018-01-01.

Abstract

Photodynamic therapy (PDT) is a technique that combines light's interaction with a photoactive substance to promote cellular death and that has been used to treat a wide range of maladies. Cancer is among the leading causes of death worldwide and has been a central issue assessed by PDT research and clinical trials over the last 35 years, but its efficiency has been hampered by photosensitizer buildup at treatment site. Nanotechnology has been addressing drug delivery problems by the development of distinct nanostructured platforms capable of increasing pharmacological properties of molecules. The association of nanotechnology's potential to enhance photosensitizer delivery to target tissues with PDT's oxidative damage to induce cell death has been rising as a prospect to optimize cancer treatment. In this study, we aim to verify and compare the efficiency of PDT using redox-responsive silica-based nanoparticles carrying protoporphyrin IX (PpIX) in vitro, in both tumor and healthy cells. Dose-response experiments revealed the higher susceptibility of murine melanoma cells (B16-F10 cell line) to PDT (630 nm, 50 J/cm(2)) when compared to human dermal fibroblasts (HDFn): after 24 h of incubation with 50 mu g/mL nanoparticles solutions, approximately 80 % of B16-F10 cells were killed, while similar results were obtained in HDFn cultures when solutions over 150 mu g/mL were used. Uptake and ROS generation assays suggest increased nanoparticle internalization in the tumor cell line, in comparison with the healthy cells, and greater ROS levels were observed in B16-F10 cells. (AU)

• FAPESP's process: 15/50471-5 - Multifunctional hybrid nanoparticles to enhance photodynamic therapy (PDT) and photodynamic inactivation (PDI) efficacy
• Grantee: Vanderlei Salvador Bagnato
• Support Opportunities: Regular Research Grants
• FAPESP's process: 13/07276-1 - CEPOF - Optics and Photonic Research Center
• Grantee: Vanderlei Salvador Bagnato
• Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC
• FAPESP's process: 09/54035-4 - Facility for advanced studies of biosystems and nanostructured materials
• Grantee: Igor Polikarpov
• Support Opportunities: Multi-user Equipment Program